{"id":17172,"date":"2020-10-22T11:00:58","date_gmt":"2020-10-22T11:00:58","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/blog\/renasci-dio-mouse-model-glp-1-semaglitude\/"},"modified":"2020-10-22T11:00:58","modified_gmt":"2020-10-22T11:00:58","slug":"renasci-dio-mouse-model-glp-1-semaglitude","status":"publish","type":"blog","link":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/renasci-dio-mouse-model-glp-1-semaglitude\/","title":{"rendered":"The dietary-induced obese (DIO) mouse: A robust platform for the development of anti-obesity pharmacotherapies"},"content":{"rendered":"

There is a growing need for efficacious\u00a0anti-obesity<\/span><\/a>\u00a0<\/span>treatments that produce clinically meaningful, sustained weight loss and ultimately reduce the risk of developing associated metabolic comorbidities, such as\u00a0diabetes<\/span><\/a>,\u00a0non-alcoholic steatohepatitis (NASH)<\/a><\/span>\u00a0and cardiovascular disease (CVD).<\/p>\n

Of particular promise is the array of new pharmacological analogues of the glucagon-like peptide 1 (GLP-1), as well as other incretin-based approaches.<\/p>\n

As such, in a continued effort to validate our models with clinically relevant comparators, we recently demonstrated that the long-acting GLP-1 receptor agonist, Semaglutide, was efficacious in our mouse model of dietary induced obesity (DIO).<\/p>\n

We showed that twice-weekly administration of Semaglutide produced an impressive\u00a024% reduction in body weight<\/strong>, which was associated with a\u00a033% reduction in food intake<\/strong>,\u00a057% decrease in adiposity<\/strong>\u00a0and\u00a0improved glucose control<\/strong>. These findings agree with the effects currently being reported in the clinic, and further demonstrate the predictive validity of our DIO mouse model for the development of anti-obesity pharmacotherapies.<\/p>\n

\u00a0<\/p>\n

Semaglutide reduced body weight by 24% and decreased cumulative food intake by 33% in the DIO mouse model:<\/span><\/h4>\n

\"\"<\/p>\n

\u00a0<\/p>\n

Semaglutide decreased overall adiposity by 57% in the DIO mouse model:<\/span><\/h4>\n

\"\"<\/p>\n

\u00a0<\/p>\n

Semaglutide improved glucose tolerance during an oral glucose challenge in the DIO mouse model:<\/span><\/h4>\n

\"\"<\/p>\n

\u00a0<\/p>\n

Semaglutide decreased liver lipids (triglycerides, cholesterol, NEFA) in the DIO mouse model:<\/span><\/h4>\n

\"\"<\/p>\n

\u00a0<\/p>\n

Importantly, our DIO mouse model is generated in-house by feeding a diet closely resembling the fat content of the western diet. Mice are ready to use \u201coff the shelf\u201d, therefore enabling a quick start to your study and a seamless transition from DIO induction phase to treatment.<\/p>\n

\u00a0<\/p>\n

Sygnature has specialised in animal models of metabolic diseases\u00a0(formerly under the name RenaSci)\u00a0for over 19 years and is an established provider of pre-clinical in vivo<\/em>\u00a0pharmacology services in this area.<\/h4>\n

We offer a range of assays and\u00a0in vivo<\/em>\u00a0models to assess the therapeutic potential of novel drugs to treat obesity:<\/p>\n